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ABSTRACT
Introduction: Proliferative diabetic retinopathy (PDR)
is the main cause of severe visual loss in people with
diabetes mellitus. The standard treatment for this
condition is panretinal photocoagulation (PRP).
This laser treatment is inherently destructive, with
predictable adverse effects on visual function, and a
safer alternative is required. Intravitreal injection of
vascular endothelial growth factor (VEGF) inhibitors
can induce short-term regression of retinal
neovascularisation. The aim of this randomised
controlled trial is to determine the efficacy, safety and
cost-effectiveness of intravitreal aflibercept, an inhibitor
of VEGF-A, VEGF-B and placental growth factor (PLGF),
in PDR, and to investigate the impact on local
oxygenation.
Methods and analysis: This is a phase IIb
randomised controlled single-masked multicentre
clinical trial to determine the impact of repeated
intravitreal aflibercept injections in the treatment and
prevention of PDR. 220 participants with treatment-
naïve or treated but active retinal neovascularisation in
at least one eye will be randomly allocated 1:1 to
intravitreal aflibercept injections or PRP for a period of
52 weeks. The primary outcome is the change in best-
corrected visual acuity in the study eye at 52 weeks.
Secondary outcomes include changes from baseline
in other visual functions, anatomical changes and
cost-effectiveness. Ocular and non-ocular adverse
events will also be reported over 52 weeks.
Ethics and dissemination: The study has been
approved by the National Research Ethics Service
(NRES) committee with respect to scientific content
and compliance with applicable research and human
subjects’ regulations. Findings will be reported through
scientific publications and research conferences. The
results of this study will provide clinical evidence for
the feasibility, efficacy safety and cost-effectiveness of
intravitreal aflibercept for PDR.
Trial registration number: ISRCTN 32207582.
BACKGROUND
Diabetic retinopathy (DR) is the most
common complication of diabetes and is
caused by progressive damage to the retinal
blood vessels with increasing duration of dia-
betes.1 The two major sight-threatening com-
plications of DR are diabetic macular
oedema (DMO) and proliferative diabetic
retinopathy (PDR).2 3 PDR is characterised
by growth of new blood vessels that can cause
severe sight loss as a result of vitreous haem-
orrhage, retinal detachment and neovascular
glaucoma (NVG).
Multiple molecular mechanisms are
involved in the pathogenesis of DR. However,
a ﬁnal common pathway involves retinal
hypoxia and consequent upregulation of vas-
cular endothelial growth factor (VEGF).4
Therefore, treatment options for PDR aim
either to promote retinal oxygen availability
or to inhibit VEGF. Panretinal photocoagula-
tion (PRP) is applied to the peripheral
retinal tissue to ablate areas of the peripheral
retina and thereby reduce retinal oxygen con-
sumption.5 Increased oxygen availability in
an unlasered retina downregulates VEGF pro-
duction, inducing regression of retinal neo-
vascularisation (NV). However, PRP-induced
regression of new vessels is variable, and
although timely PRP can protect visual acuity,
serious adverse effects are common.3 6 The
development or worsening of pre-existing
macular oedema causes vision loss in 13%.
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In addition, loss of peripheral vision, night vision or con-
trast sensitivity affects nearly 5%. Non-responders and
severe cases may also require vitrectomy. Nine-month
follow-up of 209 eyes with PDR treated with PRP in the
National Health Service (NHS) showed that 46% did not
reach the driving standard, of whom 13% had a poor
visual acuity outcome of ≤6/60 Snellen.6 An alternative
treatment option that could either obviate or delay the
need for PRP treatment for PDR would therefore be
desirable.
Novel intravitreal anti-VEGF therapies including aﬂi-
bercept, ranibizumab and bevacizumab have substan-
tially improved the treatment prognosis for a wide range
of ocular diseases, including neovascular age-related
macular degeneration, DMO and retinal vein occlusions.
Anti-VEGF treatment has superseded macular laser treat-
ment and is now the standard of care for DMO involving
the central macula (http://www.nice.org.uk). Several
clinical and preclinical studies indicate that VEGF is a
key mediator in the development of retinal NV.
Injection of VEGF into the eye of a non-human primate
stimulates growth and permeability of new vessels on the
retina, simulating PDR, and also induces NVG.7 There is
also clear evidence that hypoxic retina produces VEGF.8
Levels of VEGF mRNA and protein are elevated in a
manner that is spatially and temporally consistent with
the role for VEGF in the growth of new vessels.9 VEGF
levels are highest in ocular ﬂuid in patients with PDR
compared with other retinal diseases.10 Evidence in
support of a direct role of anti-VEGF agents blocking
retinal new vessel growth has also been reported using a
soluble VEGF receptor, anti-VEGF aptamers and
VEGFR1-neutralising antisera.11 12 Recent evidence also
indicates that monthly anti-VEGF treatment can reduce
the severity and delay the progression of DR over 24
months.13 Several case series using different anti-VEGF
agents have shown that anti-VEGF therapy is effective in
causing transient regression of retinal NV in PDR.14 The
impact of this treatment on visual function and the
effects of these agents on retinal NV compared with PRP
remain unclear. It is possible that a long-acting
anti-VEGF agent such as aﬂibercept may be sufﬁcient to
preclude the need for laser treatment as long as the eye
continues to receive the treatment. Accordingly, we need
to investigate this further by conducting a robust multi-
centre randomised controlled trial comparing the efﬁ-
cacy, safety and cost-effectiveness of repeated intravitreal
aﬂibercept relative to PRP in treating and preventing the
recurrence of PDR.
Currently, there are two multicentre trials evaluating
the efﬁcacy of ranibizumab in PDR (clinicaltrials.gov).
However, these studies are including only participants
previously untreated with high-risk PDR, a group that is
less prevalent in the UK owing to the relatively prompt
managment of early PDR identiﬁed by the nationwide
screening programmes. Furthermore, these trials
exclude cases that have been partially treated or are
poorly responsive to prior laser therapy. The aim of the
proposed study is to determine the impact of anti-VEGF
therapy in a typical UK patient cohort with PDR.
A mechanistic substudy will further explore the patho-
genesis of PDR in terms of whether repeated intravitreal
aﬂibercept retards the progression of PDR by (1)
causing regression of retinal NV, (2) improving oxygen
saturation within retinal vessels and (3) reducing quanti-
ﬁable areas of retinal non-perfusion.
STUDY DESIGN
This is a phase IIb randomised controlled single-masked
multicentre clinical trial that will test the non-inferiority
of intravitreal aﬂibercept to the standard of care of PRP
on 220 participants with PDR at 52 weeks. Forty willing
participants (20 in each arm) will also undergo retinal
oximetry as part of the mechanistic substudy (see ﬁgure 1
for the trial ﬂow diagram).
Inclusion criteria:
1. Participants of either sex aged 18 years or over.
2. Diagnosis of diabetes mellitus (type 1 or 2).
3. Best-corrected visual acuity (BCVA) in the study eye
better than or equal to 54 Early Treatment Diabetic
Retinopathy Study (ETDRS) letters (Snellen visual
acuity 6/24).
4. Visual acuity in fellow eye ≥2/60.
5. PDR with no evidence of previous PRP or presence
of new or persistent retinal NV despite prior PRP
that (a) requires treatment in the opinion of the
investigator and (b) there is sufﬁcient space in the
peripheral retina to perform more PRP treatment. In
patients with both eye involvements, the eye with no
PRP or the least number of PRP burns will be rando-
mised as the study eye. If both eyes have had no pre-
vious PRP, the eye with the better visual acuity will be
randomised as the study eye. However, patients will
be offered a choice and can opt for the ‘worse seeing
eye’ to be randomised.
6. Media clarity, pupillary dilation and participant
cooperation sufﬁcient for adequate fundus photo-
graphs. Eyes with mild pre-retinal haemorrhage or
mild vitreous haemorrhage that does not interfere
with clear visualisation of the macula and optic disc
are eligible for this study.
7. Ability to give informed consent.
8. Women should use effective contraception, be post-
menopausal for at least 12 months prior to trial entry,
or surgically sterile.
Key exclusion criteria include coexistent ocular
disease in the study eye that may interfere with visual
outcome, treatment or trial assessments; moderate or
dense vitreous haemorrhage that prevents clear visualisa-
tion of the macula and/or optic disc or prevents PRP
treatment; signiﬁcant ﬁbrovascular proliferation or trac-
tional retinal detachment in the posterior pole; prior
vitrectomy; presence of centre-involving macular
oedema at baseline; iris or angle NV and NVG; antici-
pated need for cataract extraction or vitrectomy within
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the next 12 months; previous intravitreal anti-VEGF or
steroid treatment for DMO in the past 4 months; PRP in
the past 8 weeks and previous Iluvien therapy.
Key exclusion criteria that apply to systemic conditions
include a glycated haemoglobin (HbA1c) level of more
than 12%; blood pressure of more than 170/
110 mm Hg; myocardial infarction, stroke, transient
ischaemic attack, acute congestive cardiac failure or any
acute coronary event within 6 months of randomisation;
dialysis or renal transplant; pregnant or breastfeeding
women or males and females who do not agree to use
effective contraception during the study and for at least
3 months after the study has ﬁnished. Participation in an
investigational trial involving an investigational medi-
cinal product within 30 days of randomisation is also an
exclusion.
Figure 1 The trial design showing the assessments in each arm (CTU, Clinical Trials Unit).
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Randomisation
Randomisation will be via a bespoke web-based random-
isation system hosted at the King’s Clinical Trials Unit on
a secure server. In total, 220 adult patients with PDR will
be randomised 1:1 at the level of the individual using
the method of minimisation incorporating a random
element. The minimisation factors will be PDR status
(treatment naïve vs active retinal NV post PRP), HbA1c
(<8%, 8–10%, >10%), diastolic blood pressure (>90 vs
≤90 mm Hg), BCVA (54–69 vs ≥70 letters) and trial site.
TRIAL INTERVENTIONS
Intervention arm
Aﬂibercept (Bayer plc, Regeneron, Inc) is approved by
the Food and Drug Administration and European
Medicines Agency for wet age-related macular degener-
ation and macular oedema due to central retinal vein
occlusion. Aﬂibercept will be provided by Bayer
Healthcare Ltd. in accordance with its marketing author-
isation. The Clinical Trials Manufacturing and Supplies
Department, Pharmacy Production Department, Royal
Free Hospital NHS Foundation Trust, will be responsible
for packaging, labelling and Qualiﬁed Person (QP)
releasing the drug prior to distribution to site. The phys-
ical, chemical and pharmaceutical properties, and for-
mulation of aﬂibercept are provided in the current
version of the SPC. The drug will be delivered in exactly
the same dose and formulation as notiﬁed in the mar-
keting authorisation for wet age-related macular degen-
eration and macular oedema due to central retinal vein
occlusion.
All study eyes randomised to receive aﬂibercept will
receive an intravitreal injection of aﬂibercept 2 mg/
0.05 mL at baseline and at 4 and 8 weeks. Further treat-
ment at week 12 is determined by the degree of
regression of NV of disc and elsewhere on clinical exam-
ination with adequate visualisation of the entire retina
and compared to the seven-ﬁeld colour photographs or
wide-ﬁeld photography at screening. The patients will be
categorised according to treatment response into three
groups as shown in table 1: (1) no regression (2) partial
regression and (3) total regression.
From week 16, further treatment is determined by
both regression and reactivation of NV on clinical exam-
ination with adequate visualisation of the entire retina
and by comparing the four-ﬁeld colour photographs or
wide-ﬁeld imaging done in the previous visit. The treat-
ment response will be categorised into four groups: (1)
no regression, (2) partial regression, (3) total regression
and (4) reactivation as shown in table 1.
Further ﬁelds of colour retinal photographs or ﬂuor-
escein fundus angiography may be performed at any
visit if there is any doubt that a clinical feature repre-
sents retinal NV.
Aﬂibercept treatment may be deferred if an eye
experienced an adverse event due to prior intravitreal
injection, in cases of total vitreous haemorrhage with no
clear view of the fundus, disease progression where risks
of an injection outweigh the beneﬁts or if the interval
since the last aﬂibercept injection is <4 weeks.
Comparator arm
PRP therapy, the current standard of care, will be the
comparator and will be delivered as per routine clinical
practice with emphasis on targeting retinal non-
perfusion areas. In brief, treatment-naïve patients requir-
ing PRP treatment will for the ﬁrst time be initiated on
it and completed in fractionated 2 weekly sessions up to
and may include up to week 4 and then reviewed at
week 12. Participants with persistent active new vessels
Table 1 Definition of regression patterns of retinal NV
Regression
pattern Definitions of regression patterns (compared to previous visit)
No regression Any one or more of the following:
A. No decrease in size or density of active NV
B. Increase in area of active NV
C. De novo active NV (flat or elevated) in an eye with pre-existing active NVs that have not regressed or
partially regressed since the previous visit
D. Iris or angle NV and NVG
Partial regression Persistent active NV but a decrease in size or density of NV from the previous visit
Total regression Any one or more of the following:
A. Complete regression of NVE/D
B. Regression of NV tissue to avascular fibrotic tissue
C. Quiescent NV defined as inactive NV that, in the opinion of the investigator, does not require any
further treatment
Reactivation Reactivation can occur at any visit from week 16 and is defined as one or more of the following :
A. Recurrence of NV
B. De novo NV (flat or elevated) following at least 8 weeks of total regression
NV, neovascularisation; NVD, neovascularisation disc; NVE, neovascularisation elsewhere; NVG, neovascular glaucoma;.
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that have had PRP previously and are randomised to the
PRP arm will receive ﬁll-in PRP in 1–2 two weekly ses-
sions. From week 12, all patients in the PRP arm will be
assessed for treatment response every 8 weeks and cate-
gorised exactly as the aﬂibercept arm.
PRP treatment can be done using any PRP delivery
system including indirect PRP. If PRP has to be done as
a day case, this should not be recorded as a serious
adverse event (SAE) despite hospitalisation. PRP may be
deferred if the media are too hazy to perform the pro-
cedure. In the ‘no regression category’ in both arms,
PRP may be deferred if, in the opinion of the investiga-
tor, the eye has had adequate PRP and there is insufﬁ-
cient space for further ﬁll-in PRP.
Figure 2 shows the categorisation and treatment of
patients from week 16.
Masking
The research optometrists are the primary outcome
assessors and will conduct the visual acuity tests at
screening and at 12 and 52 weeks. The other tests of sec-
ondary outcome measures of visual ﬁelds and optical
coherence tomography will also be performed by
masked technicians. The participants will be advised at
enrolment that they must not discuss the study arm they
are in with these assessors. The retinal photographs at
screening and at 12 and 52 weeks and fundus ﬂuores-
cein angiography at screening and at 52 weeks will be
graded by masked graders in the Independent Reading
Centres within Network of Ophthalmic Reading Centres
UK (NetwORC UK). These masking procedures will
avoid both performance and detection bias. We will
describe the completeness of outcome data for each
outcome, including reasons for attrition and exclusions
from the analysis.
SAMPLE SIZE
The sample size calculation was performed using
nQuery Advisor 4.0 software. The primary outcome is
the change in BCVA measured as the ETDRS letter
score from baseline to 52 weeks. On the basis of the
objectives of this study and the potential deleterious
effects on visual function by PRP, a non-inferiority
margin of 5 L was judged to be clinically acceptable.15–18
In addition, this margin is less than the lower limit of
the 95% CI for the comparison of immediate PRP with
observation. This helps ensure that aﬂibercept is super-
ior to observation alone in the event that it is found to
be non-inferior to PRP. Therefore, in the wider patient
population, if aﬂibercept is no more than ﬁve letters
worse, then it will be deﬁned to be non-inferior. The
sample size is based on providing a 95% CI for the
between-arm difference in mean change in visual acuity
that will be sufﬁciently narrow to detect non-inferiority
(by the CI lying entirely above the margin) with high
power, while keeping a false declaration of non-
inferiority to 5% through use of a statistical test applied
at the two-sided 5% level of signiﬁcance.
Figure 2 The regression patterns (RP) of the retinal neovascularisation is classified into the following: no regression (NR); total
regression (TR); partial regression (PR) and reactivation (RAc) (PRP, panretinal photocoagulation).
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The SD of the change in visual acuity, after adjustment
for baseline, is anticipated to be 10.3, based on the esti-
mate from a relevant trial.18
With 110 patients randomised per arm (total 220),
182 will be followed up to the 52-week outcome (allow-
ing for a 17% dropout or per protocol (PP) exclusion).
This provides a 90% power to detect non-inferiority
using a two-sided 95% CI from an analysis of covariance
test with adjustment for baseline visual acuity.
OUTCOMES
Primary outcome is the change in BCVA from screening
to 52 weeks in the study eye measured in the ETDRS
letter score at 4 m.
Secondary outcomes on visual functions are to
measure the effect of intravitreal aﬂibercept therapy,
relative to PRP on additional visual function and quality
of life outcomes including change in BCVA at 12 weeks.
These include:
1. Percentage of uniocular and binocular Esterman efﬁ-
ciency scores at 52 weeks;
2. Binocular visual acuity at 52 weeks;
3. Low luminance visual acuity at 52 weeks;
4. Visual acuity outcomes in terms of visual gain or loss;
5. Contrast sensitivity measured using the Pelli Robson
chart at 52 weeks;
6. Change from baseline in vision-related quality of life
measured using NEI-VFQ-25 and RetDQol at
52 weeks. NEI-VFQ 25 is a validated tool for vision-
related quality of life.19 RetDQoL is a validated ques-
tionnaire speciﬁc for DR;20
7. Change from baseline in DR treatment satisfaction
questionnaire (RetTSQ) scores at 52 weeks. RetTSQ
is a DR treatment satisfaction questionnaire that has
taken both anti-VEGF and PRP treatment into
account when it was designed.21
8. Change from baseline in health-related quality of life
at 52 weeks (EQ-5D, ICECAP-A and client service
receipt inventory (CSRI)). The EQ-5D is a generic
health-related quality of life measure, which will be
collected at screening and at week 52 for health eco-
nomics analysis.22 The ICECAP-A is a brief question-
naire which measures individual capability and
well-being.23 A CSRI will be included to collect data
on health and social care service use frequency and
subsequent costs.
Anatomical outcomes include the regression patterns
of new vessels at 12 weeks and the regression and reacti-
vation patterns at 52 weeks. Additionally, the proportion
of patients with 1-step and 3-step improvement or wor-
sening of DR between treatment arms at 12 and
52 weeks will be reported.
Treatment-related outcomes include the proportions
of naïve PDR and non-naïve PDR eyes that do not
require PRP through 52 weeks after basic treatment of
three loading doses of aﬂibercept in the aﬂibercept arm
and after initial completion of PRP in the PRP arm.
The safety proﬁle will be reported in terms of propor-
tion of patients developing macular oedema, any de
novo or increase in existing vitreous haemorrhage, new
or increasing tractional retinal detachment, NVG and
the requirement for vitrectomy for various indications.
Cost-effectiveness analysis
From a public sector, multiagency perspective, the
following economic analysis will be carried out:
1. Full costing of intravitreal aﬂibercept treatment and
PRP, using national/local unit costs; we will collect
information on patient service use using hospital
data and a CSRI completed by patients.
2. A primary cost-effectiveness analysis, using PRP as the
comparator. Change in BCVA will be used as the
measure of effectiveness.
3. A secondary cost-utility analysis, using the EQ-5D as
the measure of utility to generate a cost per QALY
(ICER) and Cost Effectiveness Acceptability Curve
(CEAC) for comparison with the National Institute
for Health and Care Excellence (NICE) ceiling
threshold of £20 000 to £30 000.24 25
Sensitivity analyses will be conducted to see how key
assumptions affect cost-effectiveness estimates.
Mechanistic evaluation
The outcomes of the mechanistic evaluation will include
regression of retinal NV at 12 and 52 weeks in terms of
decimal disc area units; change in retinal vessel calibre
and oxygen saturation and change in quantiﬁable areas
of retinal non-perfusion. Independent grading of retin-
opathy and changes in retinal NV will be performed by
graders in reading centres within the NetwORC UK.
DATA ANALYSIS PLAN
Primary outcome analysis
Analyses will be on an intention-to-treat (ITT) basis. The
primary outcome will be compared between arms pri-
marily at the 52-week point and secondarily at the
12-week point using a linear mixed effects model with
patient as a random effect to allow for within-patient
correlation of repeated measures over time. The ﬁxed
effects will consist of the baseline of the outcome using
the missing indicator method and any remaining mini-
misation stratiﬁers, including study site. These will be
included as main effects and interactions with times.
The test for non-inferiority will be one-sided at the 2.5%
signiﬁcance level, and presented as an estimated effect
with a two-sided 95% CI compared with the non-
inferiority margin.
For the analysis of the primary outcome, the mixed
effects model will be reﬁtted in a reduced PP popula-
tion, excluding patients found to be ineligible at entry,
and those not receiving the full randomised treatment
up to and including the 8-week visit (whether due to dis-
continuation, exclusion or other reason for missing a
randomised treatment in this period). Non-inferiority
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will only be concluded if this is declared by both the
ITT analysis and the PP analysis at 52 weeks.
Non-inferiority will also be assessed in ITT and PP popu-
lations at 12 weeks.
Secondary outcome analysis
Secondary outcome analyses will be on an ITT basis
only, and assessed with tests at the two-sided 5% level of
signiﬁcance. Continuous outcomes will be compared
between arms using a linear mixed effects model, as spe-
ciﬁed for the primary outcome ITT analysis. Continuous
and binary outcomes will be reported as differences in
proportions assessed using χ2 tests. All tests will be two-
sided at the 5% signiﬁcance level and interpreted cau-
tiously with a focus on interpreting effect sizes with 95%
CIs. Safety outcomes will be reported as unadjusted
patient proportions and rates within and between arms
with 95% CIs using exact methods where appropriate.
Sensitivity and other planned analyses
Sensitivity to the missing at random assumption made in
the primary outcome analysis will be undertaken to
assess sensitivity to the handling of the missing 52-week
data, and to the use of concomitant treatments, and will
be detailed in the statistical analysis plan.
If non-inferiority is concluded, superiority will be
assessed, and also the effect on the primary outcome
will be presented with 95% CI within baseline retinop-
athy status subgroups: naïve PDR and non-naïve PDR.
ETHICAL ISSUES
The main ethical issues in relation to this study are the
use of intravitreal injections. However, this is now the
standard of care for wet age-related macular degener-
ation, DMO and retinal vein occlusion. There are at
least ﬁve extra visits that the participants need to
undergo in excess of the standard of care. The precise
risks and beneﬁts of participating in the clinical study
will be outlined in patient information sheets, formu-
lated with service user involvement.
Participants in the mechanistic substudy have to
undergo retinal oximetry, an additional non-invasive
imaging of the retina at baseline, as well as at 12 and
52 weeks and at the point of withdrawal. There are no
known risks for retinal oximetry.
Participants will be treated with the standard of care
(PRP) if the disease recurs after they have completed
the study. This information is reﬂected in the patient
information sheet.
Any breach of conﬁdentiality will be minimised by
adherence to the UK Data Protection Act 1998 and the
approved protocol. The trial will be employing an elec-
tronic data capture system (Infermed MACRO). Access to
the system will be restricted to authorised site personnel.
Aﬂibercept will be delivered in exactly the same dose
and formulation as notiﬁed in the marketing authorisa-
tion for wet age-related macular degeneration and
macular oedema due to central retinal vein occlusion.
All adverse events will be recorded in the electronic case
report form (eCRF) throughout the study regardless of
their severity or relation to study participation.
The protocol is approved by the National Research
Ethics Service Committee London—South East (14/
LO/0203). The chief investigator will submit an annual
report of all SAEs to the Sponsor, and the Research
Ethics Committee and the MHRA. The Data Monitoring
and Ethics Committee (DMEC) will be provided listings
of all SAEs on an ongoing basis.
The study may be prematurely discontinued on the
basis of new safety information, or for other reasons
given by the DMEC and/or Trial Steering Committee
(TSC), Sponsor or Research Ethics Committee
concerned.
DISSEMINATION PLAN
The research will be published in high-impact ophthal-
mology and diabetes journals and presented in scientiﬁc
meetings in the retinal section in ophthalmology. We
also plan to present in key conferences on diabetes. Each
participant will receive a summary of the results and dis-
cussion. The study results will also be disseminated to the
Diabetes Research Network and Diabetes UK so that
service users and health professionals will be informed of
the results. All stakeholders including health policy-
makers will have access to the ﬁndings of this research.
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